Clinical Trials in Brazil / NCT02338947
Active, not recruiting Not applicable

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

NCT02338947 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2019-01-01
Last updated
2025-03-05

Condition(s) studied

Frail ElderlyCoronary Artery Disease

Investigational drug(s) / intervention(s)

Off-pump coronary-artery bypass graftingOn-pump coronary-artery bypass grafting

Off-pump coronary-artery bypass grafting: Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time \>200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.

On-pump coronary-artery bypass grafting: Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time \>480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.

Study summary

Frailty is defined as a geriatric syndrome of impaired resiliency to stressors (such as cardiac surgery) that has been delineated recently in the cardiovascular literature. One of the most controversial areas of cardiac surgery has been whether off-pump coronary artery bypass grafting (OPCAB) surgery is superior to conventional on-pump coronary artery bypass grafting (CABG) surgery. There is an ongoing debate about the benefits and disadvantages of OPCAB surgery and we believe that this remains an important technique for the improvement of coronary surgery. The benefits of CABG surgery in frail patients are still undetermined. The aim of this study is to clarify the potential benefit of OPCAB surgery in pre-frail and frail patients by comparing off-pump versus on-pump CABG in these patients.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria: \- Participants aged ≥60 years with the indication of myocardial revascularization with ≥2 criteria of frailty by Fried Frailty Criteria, and suitable to undergo either Off-pump or On-pump CABG. Exclusion criteria: \- Patients with the indication of angioplasty or another procedure in addition to CABG; patients who underwent an emergency operation (within 24 hours after hospital admission); patients who underwent previous cardiac surgery, even with other approaches than median sternotomy; patients who do not have free, prior and informed consent to participate in this study.

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Emory University School of Medicine Atlanta Georgia
Hospital de Messejana Fortaleza Ceará
Hospital das Clínicas Samuel Libânio Pouso Alegre Minas Gerais
Hospital Alberto Urquiza Wanderley João Pessoa Paraíba
Instituto Nacional de Cardiologia de Laranjeiras Rio de Janeiro Rio de Janeiro
Beneficência Portuguesa de São Paulo São Paulo São Paulo
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo São Paulo São Paulo

More University of Sao Paulo General Hospital trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02338947 on ClinicalTrials.gov ↗ ← All trials in Brazil